Biomarkers and clinical trial design

Co-chairs

Linda-Gail Bekker

Desmond Tutu HIV Centre, South Africa

Carey Hwang

Vir Biotechnology, United States

Speakers

Sayan Dasgupta

Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, University of Washington, USA

Ying Huang

Fred Hutchinson Cancer Research Center, University of Washington, USA

Evaluating the surrogacy of multiple vaccine-induced immune response biomarkers in HIV vaccine trials

Tomas Hanke

University of Oxford

Larry Corey

HVTN, USA

Hanneke Schuitemaker

Janssen Vaccine Prevention, the Netherlands

What biomarkers for HIV vaccine efficacy trials?

Yunda Huang

Fred Hutchinson Cancer Research Center, University of Washington, USA

PT80: A neutralization titer biomarker for antibody-mediated prevention of HIV-1 acquisition

Marco Cavaleri

European Medicines Agency, the Netherlands

A regulator perspective on the use of biomarkers as surrogate endpoints

Myron Cohen

The University of North Carolina at Chapel Hill (TBC)

Moupali Das

Gilead Sciences

Daisy Ouya

AVAC

Can biomarkers of efficacy be included in the design of efficacy trial and how?